Hillsdale Investment Management Inc. Regeneron Pharmaceuticals, Inc. Transaction History

Hillsdale Investment Management Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 09, 2023	SELL	$692.45 - $844.37 $20,773 - $25,331	-30 Reduced 5.56%	510 $419,000
Q2 2023 Aug 11, 2023	BUY	$700.03 - $830.35 $378,016 - $448,389	540 New	540 $388,000
Q2 2022 Aug 12, 2022	SELL	$548.35 - $738.84 $21,934 - $29,553	-40 Closed	0 $0
Q1 2022 Apr 28, 2022	SELL	$595.12 - $698.43 $595,120 - $698,430	-1,000 Reduced 96.15%	40 $28,000
Q4 2021 Feb 07, 2022	BUY	$543.48 - $670.97 $565,219 - $697,808	1,040 New	1,040 $657,000
Q4 2020 Feb 09, 2021	SELL	$478.3 - $607.98 $365,899 - $465,104	-765 Closed	0 $0
Q2 2020 Aug 11, 2020	SELL	$493.32 - $643.92 $98,664 - $128,783	-200 Reduced 20.73%	765 $477,000
Q1 2020 May 12, 2020	SELL	$336.18 - $494.43 $119,343 - $175,522	-355 Reduced 26.89%	965 $471,000
Q1 2019 May 13, 2019	BUY	$372.08 - $439.57 $7,441 - $8,791	20 Added 1.54%	1,320 $542,000
Q2 2018 Aug 13, 2018	BUY	$284.6 - $344.99 $369,980 - $448,487	1,300 New	1,300 $448,000

1,534

83.6M

1.22M

1.51M

Ticker REGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,190,000
Market Cap $75.3B
Description
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...

Get notified when there are updates to the investment portfolio of Hillsdale Investment Management Inc., based on Form 13F filings with the SEC.

Stay updated on Hillsdale Investment Management Inc. with notifications on news.